Is HRT safe? It's the question almost every woman asks first about hormone replacement therapy, and it's the one that can't be answered in isolation. Safety in hormone care depends on who you are, when you start, what you take, and how closely it's monitored. Here's what the evidence actually supports, where it's still unsettled, and what a responsible evaluation looks like.
Is HRT safe?
For most healthy women under 60 who are within about 10 years of menopause and have bothersome symptoms, the balance of benefit and risk is generally favourable. That's the position of The North American Menopause Society in its 2022 hormone therapy statement, and it's a meaningful shift from how the same question was answered in 2003.
But "generally favourable" isn't the same as safe for everyone. The risks are real, they vary by regimen and by person, and a handful of medical histories rule it out entirely. The more useful question is whether it's appropriate for you, at this stage, with proper evaluation and monitoring.
What the Women's Health Initiative actually found
The Women's Health Initiative is the reason a generation of women stopped hormone therapy, so it's worth understanding what it tested. WHI was a large randomized trial in postmenopausal women aged 50 to 79, with an average age at enrollment of about 63. It ran two separate hormone arms, and they didn't produce the same result.
| Factor | Estrogen plus progestin | Estrogen alone |
|---|---|---|
| Who it was given to | Women with a uterus | Women who'd had a hysterectomy |
| Stopped early in | 2002 | 2004 |
| Breast cancer | Increased | Not increased, and lower in long-term follow-up |
| Stroke | Increased | Increased |
| Blood clots | Increased | Increased |
| Hip fracture | Reduced | Reduced |
In the combined arm, the breast cancer signal that drove most of the headlines worked out to roughly eight additional cases per 10,000 women per year. That's a real increase and it shouldn't be waved away. It's also a smaller absolute number than most people carry in their heads, and it didn't appear in the estrogen-alone arm at all.
One more finding rarely made the news. When Manson and colleagues published 18 years of follow-up in JAMA in 2017, neither regimen was associated with an increase in all-cause mortality.
Why the timing of starting matters
The average WHI participant was more than a decade past menopause when she started treatment. That detail is the whole argument. Starting estrogen in a 63 year old with established atherosclerosis appears to behave differently from starting it in a 52 year old at the point her own levels are dropping.
Clinicians call this the timing hypothesis, and it's why current guidance is written around age and years since menopause rather than a blanket yes or no. Be precise about what it is, though. It's a well supported interpretation of subgroup and follow-up data, not a settled fact, and it's a reason to individualize the decision rather than to treat hormone therapy as risk free.
Formulation and route change the risk profile
What you take and how it enters your body isn't a detail. If you still have a uterus, estrogen has to be paired with a progestogen to protect the endometrial lining, because unopposed estrogen raises the risk of endometrial hyperplasia and cancer. If you've had a hysterectomy, estrogen alone is standard.
Route matters too. Observational studies have consistently associated transdermal estrogen with a lower clot risk than oral, which is why patches and gels are often preferred for women with clotting risk factors. That evidence isn't from randomized trials, so it informs the choice without settling it. Low dose vaginal estrogen for genitourinary symptoms is a different category again, with minimal systemic absorption and a different risk profile.
Wondering whether hormone therapy is appropriate for you?
A licensed clinician reviews your history, your symptoms, and your labs before anything is recommended.
Start with an evaluation
When hormone therapy isn't appropriate
Some histories take systemic hormone therapy off the table, and no amount of individualizing changes that. It's the part of the conversation that marketing copy skips, and the part that matters most.
Common contraindications include:
- A personal history of breast cancer or another estrogen sensitive cancer
- Unexplained vaginal bleeding that hasn't been worked up
- A history of blood clots in the legs or lungs, or a known clotting disorder
- Prior stroke or heart attack
- Active liver disease
- Known or suspected pregnancy
Family history, migraine with aura, high blood pressure, and cardiovascular risk factors don't automatically rule it out, but they change the conversation and sometimes the route. Bring all of it to the evaluation.
Perimenopause, and when evaluation makes sense
Menopause isn't a single moment. It's confirmed only in hindsight, after 12 consecutive months without a period, and the years leading up to it are where most women get confused. During perimenopause hormone levels fluctuate rather than steadily decline, which is why symptoms come and go and why a single lab draw can look reassuringly normal on a bad week.
Evaluation is worth considering when you notice:
- Persistent changes in sleep, mood, or temperature regulation that don't track with lifestyle
- Symptoms that fluctuate week to week rather than following a clear pattern
- Changes that begin earlier than you expected them to
- Cycle changes alongside symptoms you'd otherwise have written off
Evaluation doesn't mean treatment. Testing establishes a baseline and gives you something to decide from. Plenty of women test, learn what's happening, and choose to do nothing for now. That's a legitimate outcome.
Estrogen, progesterone, and testosterone
These three don't work in isolation, which is why chasing one number rarely helps. Estrogen receptors are distributed through bone, brain, and blood vessels, which is why its decline gets felt in so many places at once. Progesterone's role differs: alongside protecting the uterine lining, oral micronized progesterone is usually taken at bedtime because it tends to be sedating. Our guide on estrogen versus progesterone and why balance matters more than levels goes deeper on the interaction.
Testosterone deserves a more careful answer than it usually gets. Women do produce it and levels decline with age, but the 2019 Global Consensus Position Statement on testosterone therapy for women concluded that the only indication with sufficient evidence behind it is low sexual desire in postmenopausal women. It found the evidence insufficient for energy, mood, bone density, or general wellbeing, and no testosterone product is FDA-approved for women. If you're being offered testosterone for fatigue, that's worth questioning. More in our post on testosterone replacement therapy for women.
Frequently Asked Questions
Where to go from here
Hormone therapy isn't about reversing age or eliminating every symptom. It's about understanding what's changing, getting an honest read on your own risk, and deciding with a clinician who monitors it over time rather than setting it once and walking away.
Start with a hormone evaluation and a licensed clinician will review your history, symptoms, and labs before recommending anything.
Medical disclaimer. This article is for informational purposes only and does not constitute medical advice. Hormone therapy is prescription-only and requires evaluation by a licensed medical provider. It isn't appropriate for everyone, and the balance of benefit and risk differs meaningfully from one woman to the next. Always consult a qualified healthcare provider before starting, changing, or stopping any treatment.
